Teva Pharmaceutical has completed patient enrolment for the Glatiramer Acetate Low-Frequency Administration trial of Copaxone (glatiramer acetate injection) as a treatment for multiple sclerosis.
The enrolment of over 1,400 patients with relapsing-remitting multiple sclerosis at 180 sites in the US, Europe and Israel was completed in May 2011.
The international Phase III trial is designed to examine the efficacy, safety and tolerability of the drug versus a placebo.
The results from the trial are expected in Q2 2012.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData